BioLineRx (NASDAQ:BLRX) & Lipocine (NASDAQ:LPCN) Head to Head Survey

BioLineRx (NASDAQ:BLRX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares BioLineRx and Lipocine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLineRx	-23.38%	-16.11%	-7.20%
Lipocine	-487.00%	-59.30%	-53.37%

Insider and Institutional Ownership

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for BioLineRx and Lipocine, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1	0	1	1	2.67
Lipocine	1	0	1	1	2.67

BioLineRx currently has a consensus price target of $26.00, suggesting a potential upside of 1,020.69%. Lipocine has a consensus price target of $15.00, suggesting a potential upside of 105.20%. Given BioLineRx’s higher probable upside, equities research analysts clearly believe BioLineRx is more favorable than Lipocine.

Risk & Volatility

BioLineRx has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioLineRx and Lipocine”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$28.94 million	0.35	-$9.22 million	$0.17	13.65
Lipocine	$1.98 million	26.95	-$9.63 million	($1.69)	-4.33

BioLineRx has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Summary

BioLineRx beats Lipocine on 9 of the 12 factors compared between the two stocks.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

About Lipocine

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.